Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAmortizatization of IntangiblesAsset Writedowns and ImpairmentAsset Writedowns and ImpairmentCapital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Accured ExpensesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in IntangiblesChange in InventoryChange in InventoryChange in ReceivablesChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation & Amortization (CF)Exchange Rate EffectExchange Rate EffectFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesLong-Term Debt IssuancesLong-Term Debt RepaymentsNet Cash FlowNet Cash FlowNet IncomeOther Working Capital ChangesOther Working Capital ChangesOther financing activitiesOther financing activitiesShare-based CompensationShare-based CompensationShares IssuedShares Repurchased
Growth Metrics
Income Statement
Others
Ratios

Indivior Pharmaceuticals (INDV) Capital Expenditures (2022 - 2026)

Indivior Pharmaceuticals has reported Capital Expenditures over the past 5 years, most recently at $20.0 million for Q1 2026.

  • For Q1 2026, Capital Expenditures rose 300.0% year-over-year to $20.0 million; the TTM value through Mar 2026 reached $81.0 million, up 153.12%, while the annual FY2025 figure was $66.0 million, 127.59% up from the prior year.
  • Capital Expenditures for Q1 2026 was $20.0 million at Indivior Pharmaceuticals, down from $24.0 million in the prior quarter.
  • Over five years, Capital Expenditures peaked at $24.0 million in Q4 2025 and troughed at -$2.0 million in Q3 2022.
  • A 5-year average of $8.7 million and a median of $7.0 million in 2024 define the central range for Capital Expenditures.
  • Biggest five-year swings in Capital Expenditures: changed 0.0% in 2023 and later soared 500.0% in 2024.
  • Year by year, Capital Expenditures stood at $9.0 million in 2022, then skyrocketed by 33.33% to $12.0 million in 2023, then skyrocketed by 33.33% to $16.0 million in 2024, then skyrocketed by 50.0% to $24.0 million in 2025, then fell by 16.67% to $20.0 million in 2026.
  • Business Quant data shows Capital Expenditures for INDV at $20.0 million in Q1 2026, $24.0 million in Q4 2025, and $20.0 million in Q3 2025.